Clinical trials: Aripiprazole, completed
Tourette Syndrome
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily…
- Trial name
- NCT03487783
- Testing
- Aripiprazole Oral Solution
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Otsuka Beijing Research Institute
Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).
This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00332241
- Testing
- Aripiprazole
- Where
- 9 sites in United States
- Volunteers
- 98 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Weight, Body
Long-term Antipsychotic Pediatric Safety Trial
Main LAP01 study: The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic…
- Trial name
- LAPS (NCT03522168)
- Testing
- Risperidone, Aripiprazole
- Where
- 37 sites in United States
- Volunteers
- 509 people
- Sponsor
- Duke University
Autistic Disorder
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, tolerability and the steady-state plasma trough concentration of aripiprazole flexible-dosed in children…
- Trial name
- NCT03487770
- Testing
- Aripiprazole Oral Solution
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Otsuka Beijing Research Institute
Disruptive Mood Dysregulation Disorder
Aripiprazole Added on for DMDD in Youths With ADHD
Objectives: 1. To investigate the effectiveness of adjuvant with aripiprazole to methylphenidate for disruptive mood dysregulation disorder (DMDD) in youths with attention-deficit/hyperactivity disorder (ADHD) 2.
- Trial name
- AAOFDIYWA (NCT03358277)
- Testing
- MPH + APZ
- Volunteers
- 58 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Autistic Disorder, Asperger Syndrome
Study of Aripiprazole to Treat Children and Adolescents With Autism
The purpose of this open label study in children and adolescents is to examine the acute and long-term effects of aripiprazole on problem behaviors associated with autism spectrum disorders and development in areas which appear…
- Conditions
- Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder
- Trial name
- PAIRS (NCT00619190)
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Autism, Asperger's Disorder
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period.
- Conditions
- Autism, Asperger's Disorder, Pervasive Developmental Disorder
- Trial name
- NCT00308074
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cambridge Health Alliance
Autism
Aripiprazole in Children With Autism: A Pilot Study
This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole for 6 weeks.
- Trial name
- NCT00208533
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Drexel University College of Medicine
Schizophrenia, Metabolic Syndrome
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
The study is performed in 20 different hospitals from 19 cities in China. Three sub-projects are included. About sub-project 1, we build a clinical database system and a biological sample bank for data and samples management…
- Trial name
- NCT03451734
- Testing
- antipsychotic medications, adjunctive group, metformin and lifestyle intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Central South University
Bipolar Disorder
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications do not completely control those symptoms.
- Trial name
- NCT00221416
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Autism Spectrum Disorder
Combination Treatment for Augmenting Language in Children With ASD
The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same…
- Trial name
- PIII (NCT02574741)
- Testing
- Behavioral Therapy, Aripiprazole
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of California, Los Angeles
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418339
- Testing
- Aripiprazole
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autistic Disorder, Behavioral Symptoms
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 [NCT00332241]…
- Trial name
- NCT00365859
- Testing
- Aripiprazole
- Where
- 55 sites in United States
- Volunteers
- 330 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Fragile X Syndrome
A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome
The purpose of this study is to determine the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with Fragile X Syndrome.
- Trial name
- NCT00420459
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Bipolar Disorder
Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (Abilify) in children with subsyndromal symptoms of bipolar disorder who also have a parent with bipolar disorder and other family…
- Trial name
- NCT00194012
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Bipolar Disorder I
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for prevention of recurrence/relapse of…
- Trial name
- NCT04812379
- Testing
- Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)
- Where
- Japan
- Volunteers
- 535 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Behavioral Symptoms, Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00337571
- Testing
- Aripiprazole
- Where
- 31 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.